- Home
- DVS vs FDMT Comparison
DVS vs FDMT Comparison
Compare DVS & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVS
- FDMT
- Stock Information
- Founded
- DVS 2011
- FDMT 2013
- Country
- DVS Canada
- FDMT United States
- Employees
- DVS N/A
- FDMT N/A
- Industry
- DVS
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- DVS
- FDMT Health Care
- Exchange
- DVS Nasdaq
- FDMT Nasdaq
- Market Cap
- DVS 210.3M
- FDMT 192.2M
- IPO Year
- DVS N/A
- FDMT 2020
- Fundamental
- Price
- DVS $3.46
- FDMT $7.09
- Analyst Decision
- DVS
- FDMT Buy
- Analyst Count
- DVS 0
- FDMT 9
- Target Price
- DVS N/A
- FDMT $30.63
- AVG Volume (30 Days)
- DVS 311.5K
- FDMT 2.6M
- Earning Date
- DVS 08-13-2025
- FDMT 08-11-2025
- Dividend Yield
- DVS N/A
- FDMT N/A
- EPS Growth
- DVS N/A
- FDMT N/A
- EPS
- DVS N/A
- FDMT N/A
- Revenue
- DVS N/A
- FDMT $33,000.00
- Revenue This Year
- DVS N/A
- FDMT $9,921.62
- Revenue Next Year
- DVS N/A
- FDMT N/A
- P/E Ratio
- DVS N/A
- FDMT N/A
- Revenue Growth
- DVS N/A
- FDMT N/A
- 52 Week Low
- DVS $2.48
- FDMT $2.24
- 52 Week High
- DVS $4.15
- FDMT $17.41
- Technical
- Relative Strength Index (RSI)
- DVS 46.51
- FDMT 65.24
- Support Level
- DVS $3.26
- FDMT $6.35
- Resistance Level
- DVS $3.73
- FDMT $7.59
- Average True Range (ATR)
- DVS 0.14
- FDMT 0.59
- MACD
- DVS -0.02
- FDMT 0.05
- Stochastic Oscillator
- DVS 42.55
- FDMT 78.81
About DVS Dolly Varden Silver Corporation Common Shares
Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.